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Abstract The modular structure of HGF/SF offers a reduc-
tionist or ‘divide and rule’ approach to the analysis of structure
and function. Domain deletion experiments have established that
the N domain, kringle 1 and kringle 2 are essential for HGF/SF
activity and that truncated variants containing the N domain and
kringle 1 (NK1) or kringles 1 and 2 (NK2) can exhibit partial
agonistic or antagonistic activity depending on target cells.
Comparative modelling has been used to predict the 3D
structures of the six domains of HGF/SF. More recently,
NMR methods have shown that the N domain has a novel fold,
the charge distribution of which suggests a heparin binding site.
Crystals of NK1 indicate the relationship of this domain to the
kringle 1, offering further insights into the mechanism of domain
interactions and receptor activation.
z 1998 Federation of European Biochemical Societies.
Key words: Hepatocyte growth factor/scatter factor; Protein
domain; NMR; X-ray analysis ; Receptor activation
1. Introduction
HGF/SF [1^5], the ¢rst member of the plasminogen related
growth factor family, is composed of six domains whose
boundaries are clearly de¢ned at the sequence level. The N-
terminal domain, the so-called N domain, comprising residues
Glu-30-Asn-121 is homologous to the activation peptide of
plasminogen. A short linker peptide connects the N domain
with four copies of the kringle domain: Cys-128-Cys-206
(kringle 1), Cys-211-Cys-288 (kringle 2), Cys-305-Cys-383
(kringle 3) and Cys-391-Cys-469 (kringle 4). A linker peptide
of 24 amino acids links the forth kringle to an inactive serine
proteinase domain (Val-495-Ser-728). This peptide contains a
half-cystine residue (Cys-487) predicted to form a disulphide
bond with Cys-604 and a trypsin-like cleavage site (Gln-492-
Leu-493-Arg-494 s Val-495-Val-496-Asn-497), which is
cleaved upon conversion of single-chain pro-HGF/SF into a
two-chain molecule.
An understanding of the relationship between structure and
function in HGF/SF depends on a knowledge not only of the
conformations of the individual domains but also on their
arrangement with respect to each other, both in solution and
in complex with the HGF/SF (MET) receptor. The availabil-
ity of high-resolution structures of kringle and serine protein-
ase domains allowed us several years ago to construct three-
dimensional models of the corresponding HGF/SF domains
[6]. The models of kringles 1 to 4 of HGF/SF con¢rmed the
presence of the typical features of kringle domains, i.e. a hy-
drophobic core and a globular structure stabilized by the three
conserved disulphide bonds. The model of the serine protein-
ase con¢rmed that the usual tertiary structure could be as-
sumed, although critical substitutions a¡ected two catalytic
residues (His534Gln and Ser673Tyr). Substitutions were also
apparent in the region corresponding to the S1 speci¢city
pocket of active enzymes, notably in residues responsible for
arginine speci¢city. The unavailability of structures of homo-
logues prevented comparative modelling of the N domain.
Instead, a 3D model of the 27-residue hairpin loop, which
plays an important role in receptor binding and activity,
was constructed. The modelling was performed assuming con-
straints on the conformation that occur if the four half-cystine
residues (Cys-70, Cys-74, Cys-84 and Cys-96) exhibit the con-
nectivity of the corresponding residues in the homologous
plasminogen domain. The resulting structure suggested a he-
lix-extended strand-helix motif, with a cluster of positively
charged residues (Arg-73, Arg-76 and Arg-93) on the helical
side of the loop and a cluster of hydrophobic residues (Leu-
80, Phe-82, Ala-86, Phe-87, Val-88 and Phe-89) on the ex-
tended strand [6].
In this review we brie£y examine the experimental data on
domain deletion and truncated variants. We describe the nov-
el fold of the N domain de¢ned by NMR methods and com-
pare this to the predicted structure. We also report the prep-
aration and analysis of crystals of NK1, which de¢ne the
relationship of this domain to kringle 1, o¡ering further in-
sights into the mechanism of domain interactions and receptor
activation.
2. Domain deletion analysis and truncated variants of HGF/SF
Deletion of either the hairpin loop of the N domain, krin-
gles 1 or 2, or the serine proteinase domain (vH, vK1, vK2
and vSP) abolished biological activity, as measured by stim-
ulation of DNA synthesis or scattering of MDCK cells. In
contrast, mutants lacking kringle 3 or 4 (vK3 or vK4) showed
reduced but measurable activity [7]. These observations were
largely con¢rmed by subsequent studies in which both recep-
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tor binding and phosphorylation as well as biological activity
were investigated [8,9].
Con¢rmation of the critical role of the N domain, kringle 1
and kringle 2 in MET binding and activation has come from
studies on two truncated forms of HGF/SF containing the N
domain+kringle 1 (NK1) or the N domain+kringles 1 and 2
(NK2). NK2 was discovered as the product of an alternatively
spliced form of the primary HGF/SF transcript [11], and a
subsequent study indicated that NK2 had considerable antag-
onistic activity [12]. NK1 was ¢rst expressed as an engineered
fragment and also appeared to behave as a potent HGF/SF
antagonist [13]. Only recently has it become apparent that
NK1 also exists in vivo as a further splice variant of the
primary HGF/SF transcript [15].
Although early work suggested that both NK2 [12] and
NK1 [13] behaved as receptor antagonists, other studies in-
dicated that both proteins could act as partial agonists [14,15].
Recent experiments suggest that cell surface heparan sulphate
proteoglycans (HSPGs) promote dimerization of NK1 and
NK2 and induce an agonistic response in target cells [16].
Furthermore Merlino and colleagues [17] have demonstrated
that mice overexpressing NK1 develop all the features of
transgenic mice overexpressing full length HGF/SF, albeit in
a less severe form.
3. The structure of the N domain
Three-dimensional structural information of HGF/SF N
domain was recently obtained by NMR techniques [18]. The
overall structure of the N domain is very well de¢ned,
although Asn-77-Gly-79 and the ¢rst seven N-terminal resi-
dues could not be observed. The central part of the structure
is represented by a ¢ve-stranded antiparallel L-sheet (Fig. 1a).
This sheet is £anked on one side by a two-turn alpha helix
and on the other by extended loops, which transform into the
L-strands, forming a small sheet. The helix and two of the
strands of the central L-sheet make a hairpin-loop structure,
which is stabilized by the disulphide bridges. The topology of
the hairpin-loop region generally resembles the fold previously
predicted by the use of disulphide restraints, although the last
strand was predicted as a loose helix (Fig. 1b).
Studies of heparin binding by proteins suggest that inter-
actions take place between basic amino acids and the sulphate
and the carboxylate groups of heparin [19]. The N-terminal
domain contains a large number of lysine and arginine resi-
dues, some of which are likely to be involved in heparin bind-
ing. The NMR structure suggests that a surface area, includ-
ing Lys-60, Lys-62, Arg-73, Arg-76 and Lys-78, may serve as
a heparin binding site. This includes Arg-73 and Arg-76,
which were predicted on the basis of the model [6]. There is
now biochemical evidence that these two residues are involved
in the binding of HGF/SF to heparin [20].
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Fig. 1. a: The structure of the N domain of HGF/SF de¢ned by NMR [18]. Helices are shown in magenta, L-strands in yellow, disul¢de
bridges in red and the residues that were not well de¢ned in green. b: The hairpin loop, modelled [6] and determined by NMR [18]. The ¢gure
was produced using SETOR [10].
Fig. 2. The packing of NK1 in the crystal cell as de¢ned by molecu-
lar replacement. N domains are shown in white and green, kringle
domains in yellow and magenta (Chirgadze, unpublished). The ¢g-
ure was produced using SETOR [10].
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4. Crystallization of NK1
We have successfully expressed NK1 and NK2 fragments of
HGF/SF in the yeast Pichia pastoris and puri¢ed both pro-
teins by a combination of heparin a⁄nity and cation exchange
chromatography (J. Hepple et al., to be published). Gel ¢ltra-
tion analysis showed that yeast-derived NK1 is a monomer
while NK2 is a mixture of monomeric and dimeric species.
NK1 has been crystallized. The crystals belong to the P21
space group and di¡ract X-rays to a resolution of 2.5 Aî .
In order to place the NK1 molecule in the crystal cell we
have employed the molecular replacement method using the
crystal structure of kringle 1 of plasminogen [21] and the
solution structure of the N domain [18] as search probes.
The existence of two molecules in the asymmetric unit com-
plicated the identi¢cation of the correct molecular replace-
ment solutions. The crystal packing of the domains is shown
in Fig. 2. The structure is currently undergoing re¢nement and
the full description of the structure determination will be pub-
lished elsewhere.
5. Site-speci¢c mutants of HGF/SF
The sequence features of HGF/SF together with the results
of domain deletion experiments and the availability of 3D
models of individual domains have led to several studies in
which speci¢c residues or clusters of residues have been sub-
stituted in order to clarify their role in HGF/SF activity. The
main results of these studies can be summarized as follows:
(1) Although several studies have pointed to a critical role
of the N domain (or its hairpin loop) in receptor binding and
biological activity, a number of individual and group muta-
tions have failed so far to identify residues critical for receptor
binding within the loop itself [22]. The same study, however,
established that a cluster of residues located at the C-terminus
of the N domain (His-114, Glu-115 and Asp-117) is involved
in both receptor binding and biological activity.
(2) Substitution of at least seven amino acids in kringle 1
(Arg-197, Glu-189, Tyr-198, Glu-195, Asp-171, Gln-173 and
Ser-161) has a clear e¡ect on receptor binding and biological
activity of HGF/SF. The greatest e¡ect is seen with substitu-
tion of Arg-197 or Glu-159 which reduce receptor binding and
biological activity by s 50-fold [22].
(3) Several point mutations in the serine proteinase domain
of HGF/SF in which residues Gln-534 and Tyr-673 were re-
verted to the His and Ser residues of active serine proteinase
did not a¡ect receptor binding but markedly decreased bio-
logical activity. A similar result was obtained with the
Val692Ser mutation [9].
(4) Mutation of critical residues at the trypsin-like cleavage
site, located between the C-terminal kringle (kringle 4) and the
serine proteinase domain, abolished conversion of the single-
chain precursor form of HGF/SF (pro-HGF/SF). The result-
ing single-chain species lacked the biological activity of HGF/
SF on target cells, although it retained receptor binding
[9,23,24]. Thus, the precursor form of HGF/SF behaves like
a receptor antagonist.
6. Models for the activation of the receptor Met protein by
HGF/SF
With the exception of the insulin receptor family, all known
receptors with tyrosine kinase activity undergo a transition
from a monomeric to dimeric state upon binding of their
cognate ligand. Therefore the ligand must either possess two
binding sites or be a dimer itself. In the case of HGF/SF, the
stoichiometry of ligand-receptor interaction is still unknown.
A model for the formation of homodimers has been suggested
by Donate and colleagues [6]. This model proposed non-co-
valent interactions between kringles 2, 3 and the serine pro-
teinase domain. A lysine residue of kringle 3 in molecule 2
would interact with the lysine binding pocket of kringle 2 in
molecule 1. This model has been disproved by mutational
studies, which show that the lysine binding pocket of kringle
2 is not required for the biological activity of HGF/SF [21].
Ponting and colleagues [25] have proposed that HGF/SF
may adopt similar conformations to plasminogen. In its in-
active form, plasminogen adopts a closed, spiral structure,
maintained by interactions between the N- and C-terminal
domains while in its active form, plasminogen has an open
‘horseshoe’ conformation. Mutagenesis experiments have
shown that cleavage of the single-chain HGF/SF into a two-
chain form is required for biological activity [9]. While the
single-chain form is capable of binding Met, the cleavage to
a two-chain form probably results in a conformational change
and a rearrangement of the relative positions of the domains.
This relaxed, open conformation may allow HGF/SF to in-
teract with and directly activate Met as a monomer or alter-
natively, enable HGF/SF to dimerize before receptor activa-
tion (Fig. 3). In the case of HGF/SF, the receptor-ligand
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Fig. 3. Models for Met receptor dimerization and the role of hepa-
rin.
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complex is probably stabilized by interactions between the
serine proteinase domain(s), as residues have been identi¢ed
in this domain which are necessary for biological activity but
not receptor binding [9]. Heparin and heparan sulfates appear
to be essential for the partial agonist behavior of NK1 and
NK2 and may do so by crosslinking the N-terminal and krin-
gle 2 domains [26].
7. Conclusions and perspectives
Protein engineering experiments have provided valuable
data on the role of HGF/SF domains in receptor binding
and activation. In parallel, 3D models of the kringle and
serine proteinase domains and of the hairpin loop of the N
domain [6,9,22] have given a basis for the design of site-spe-
ci¢c mutants which enable mapping of the MET and heparin
binding sites of HGF/SF. With NMR and crystal structures
now becoming available these studies of structure and func-
tion can be placed on a ¢rmer basis.
There is now little doubt that the N domain and kringle 1
are directly involved in receptor binding and activation as
demonstrated by domain deletion experiments, several site-
speci¢c mutants and recent experiments with the NK1 frag-
ment in vitro [14] and in vivo [17].
The role of other domains, especially the serine proteinase
domain, is more di⁄cult to assess. Whereas it is clear that
deletion of this domain leads to a marked decrease in bio-
logical activity, the mechanism by which this is achieved is
less clear. Available data do not rule out that the serine pro-
teinase domain may contain a secondary binding site for the
MET receptor or alternatively, that the serine proteinase do-
main may act as a dimerization domain and allow an HGF/
SF dimer to engage two receptor molecules through their
NK1 domains. A de¢nite answer to these questions, however,
may have to wait for the structure of HGF/SF-MET com-
plexes.
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